Trial Profile
A randomized open label phase 4 study to evaluate the safety and immunogenicity of concomitant Prevenar and Meningitec compared to Prevenar alone and Meningitec alone when used as part of the routine vaccination series in healthy infants
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Jan 2011
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine group C conjugate (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate (Primary)
- Indications Meningococcal infections; Pneumococcal infections
- Focus Pharmacodynamics
- Sponsors Wyeth
- 16 Jan 2007 New trial record.